Target: ₹1,335

CMP: ₹979.20

Ami Organics, with 380+ pharma intermediates approved, over 90 per cent of the drugs in the Chronic segment pipeline and some products going off-patent at regular intervals till FY37, seems future-ready to post a strong 25 per cent CAGR through CY22-30. This with growing prominence of Chronic diseases at 7.1 per cent CAGR versus 5.6 per cent for the Acute segment through CY22-30 should further prop outlook.

Expect Ami Organics to register revenue/PAT CAGRs of 27 per cent each in FY23-25 based on a revenue CAGR of 31 per cent in pharma intermediates (FY23 – 79 per cent of revenue), with the commissioning of the Ankleshwar plant, and 29 per cent CAGR for Specialty Chemicals.

We value Ami Organics on DCF, assuming a 5 per cent terminal growth rate and 11.8 per cent cost of capital, with an average EBITDA margin of 20.6 per cent in FY23-25 and 22.9 per cent EBITDA margin through FY26-33.

We initiate with a BUY and a target price of ₹1,335. Our implied target is 32.7x P/E and 21.5x FY25E EV/EBITDA. We have not factored in the electrolyte business into our valuations. Key risks are likely higher raw material cost, inability to pass it on, regulatory hurdles and evolving technology.

comment COMMENT NOW